Form 4: Lucid Diagnostics Director Awarded Restricted Stock
Insider Transaction Report
Lucid Diagnostics Inc. director James L. Cox was granted 123,000 shares of restricted common stock, vesting in 2029.
Summary
- James L. Cox, a director of Lucid Diagnostics Inc. (LUCD), was granted 123,000 shares of the company's common stock.
- The transaction date for this grant is reported as February 20, 2026.
- These shares are restricted stock awarded under the Issuer's 2018 Equity Plan.
- The restricted stock has a single vesting date of May 20, 2029.
- The shares are subject to forfeiture if the requisite service period is not completed.
- Following this transaction, James L. Cox beneficially owns 405,120 shares of common stock.
- The acquisition price for these shares was $0, indicating a grant rather than a purchase.
Sentiment
Score: 6
Explanation: StockSavvy.ai views this as a moderately positive event, as the grant of restricted stock to a director aligns their long-term interests with shareholders, though it is a standard compensation practice.
Positives
- Grant of 123,000 restricted shares to Director James L. Cox aligns his interests with long-term shareholder value.
- The award is part of the company's established 2018 Equity Plan, indicating a structured compensation approach.
Risks
- The restricted stock is subject to forfeiture if the requisite service period is not completed by the vesting date of May 20, 2029.
Future Outlook
The restricted stock granted to Director James L. Cox is scheduled to vest on May 20, 2029, contingent upon the completion of the requisite service period.
Industry Context
StockSavvy.ai notes that Form 4 filings are routine disclosures of insider transactions, providing transparency into changes in beneficial ownership by company directors and officers. Restricted stock grants are a common component of executive and director compensation packages across various industries, designed to align management incentives with long-term company performance.
Corporate Governance
| Change Type | Description | Effective Date | Impact Assessment |
|---|---|---|---|
| Power of Attorney | James L. Cox granted Power of Attorney to Michael A. Gordon and Dennis M. McGrath to prepare and file SEC reports on his behalf, including Forms 3, 4, 5, Schedules 13D, 13G, and Forms 144. | 2023-03-10 | Enhances efficiency and ensures timely compliance with SEC reporting requirements for insider transactions. |
Related Party Transactions
- Grant of 123,000 restricted shares to James L. Cox, a director of Lucid Diagnostics Inc., under the company's 2018 Equity Plan.
Stakeholder Impact
- Shareholders: The grant of restricted stock to a director can align management's long-term interests with shareholder value, as the director's compensation is tied to future company performance.
Next Steps
- Completion of the requisite service period by James L. Cox for the restricted stock to vest.
- Vesting of 123,000 restricted shares on May 20, 2029.
Key Dates
| Date | Description |
|---|---|
| 2023-03-10 | Date James L. Cox executed the Power of Attorney for SEC filings. |
| 2026-02-20 | Transaction date for the grant of 123,000 restricted shares to James L. Cox. |
| 2026-02-24 | Date the Form 4 filing was signed by power of attorney. |
| 2029-05-20 | Single vesting date for the granted restricted stock. |
Keywords
Lucid Diagnostics, LUCD, James L. Cox, restricted stock, insider transaction, Form 4, equity plan, director compensation, stock grant
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.